Wildon Farwell

9.9k total citations · 1 hit paper
91 papers, 3.1k citations indexed

About

Wildon Farwell is a scholar working on Genetics, Molecular Biology and Surgery. According to data from OpenAlex, Wildon Farwell has authored 91 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Genetics, 46 papers in Molecular Biology and 19 papers in Surgery. Recurrent topics in Wildon Farwell's work include Neurogenetic and Muscular Disorders Research (61 papers), RNA modifications and cancer (34 papers) and Congenital Anomalies and Fetal Surgery (13 papers). Wildon Farwell is often cited by papers focused on Neurogenetic and Muscular Disorders Research (61 papers), RNA modifications and cancer (34 papers) and Congenital Anomalies and Fetal Surgery (13 papers). Wildon Farwell collaborates with scholars based in United States, Italy and Australia. Wildon Farwell's co-authors include Josef Shargorodsky, Gary C. Curhan, Eric N. Taylor, Dulcie Kermah, Orlando M. Gutiérrez, Elizabeth Lawler, Richard E. Scranton, J. Michael Gaziano, Louis D. Fiore and Basil T. Darras and has published in prestigious journals such as Neurology, JNCI Journal of the National Cancer Institute and The Lancet Neurology.

In The Last Decade

Wildon Farwell

87 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence and Characteristics of Tinnitus among US Adults

2010 681 citations Wildon Farwell et al. The American Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wildon Farwell United States	26	1.0k	1000	821	640	528	91	3.1k
Alexander Mauskop United States	27	339 0.3×	274 0.3×	342 0.4×	127 0.2×	104 0.2×	51	2.6k
Klaus Wirth Germany	37	1.3k 1.3×	985 1.0×	341 0.4×	44 0.1×	103 0.2×	154	5.2k
D. Testa Italy	29	159 0.2×	436 0.4×	545 0.7×	72 0.1×	100 0.2×	126	2.6k
Dagmar Verbaan Netherlands	29	163 0.2×	150 0.1×	244 0.3×	178 0.3×	381 0.7×	93	3.1k
Regien G. Schoemaker Netherlands	35	317 0.3×	1.0k 1.0×	485 0.6×	39 0.1×	49 0.1×	108	4.8k
Nancy Stambler United States	24	1.5k 1.5×	442 0.4×	695 0.8×	22 0.0×	190 0.4×	68	5.2k
Frédéric Adam France	28	151 0.1×	280 0.3×	458 0.6×	48 0.1×	102 0.2×	69	2.3k
Chao Han China	28	173 0.2×	785 0.8×	609 0.7×	19 0.0×	144 0.3×	179	3.0k
Tao Yan China	28	304 0.3×	766 0.8×	141 0.2×	37 0.1×	69 0.1×	75	2.4k
Michael Linnebank Switzerland	33	458 0.5×	788 0.8×	231 0.3×	22 0.0×	120 0.2×	141	3.3k

Countries citing papers authored by Wildon Farwell

Since Specialization

Citations

This map shows the geographic impact of Wildon Farwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wildon Farwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wildon Farwell more than expected).

Fields of papers citing papers by Wildon Farwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wildon Farwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wildon Farwell. The network helps show where Wildon Farwell may publish in the future.

Co-authorship network of co-authors of Wildon Farwell

This figure shows the co-authorship network connecting the top 25 collaborators of Wildon Farwell. A scholar is included among the top collaborators of Wildon Farwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wildon Farwell. Wildon Farwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wolf, Douglas C., James B Lilleker, Guillaume Bassez, et al.. (2024). 221P Initial data from the achieve trial of DYNE-101 in adults with myotonic dystrophy type 1 (DM1). Neuromuscular Disorders. 43. 104441.63–104441.63. 1 indexed citations

Wolf, Douglas C., et al.. (2023). P50 A phase 1/2 randomized, placebo-controlled, multiple ascending dose study (ACHIEVE) of DYNE-101 in individuals with myotonic dystrophy type 1 (DM1). Neuromuscular Disorders. 33. S71–S71. 1 indexed citations

Berger, Zdenek, Eugenio Mercuri, Janbernd Kirschner, et al.. (2021). Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscular Disorders. 31(4). 310–318. 15 indexed citations

Darras, Basil T., Darryl C. De Vivo, Michelle A. Farrar, et al.. (2020). Safety Profile of Nusinersen in Presymptomatic and Infantile-Onset Spinal Muscular Atrophy (SMA): Interim Results From the NURTURE and ENDEAR-SHINE Studies (1659). Neurology. 94(15_supplement). 4 indexed citations

Darras, Basil T., Charlotte J. Sumner, Francesco Muntoni, et al.. (2020). Plasma Phosphorylated Neurofilament Heavy Chain Levels Over Time in Participants With Infantile-and Later-onset SMA: Data from the SHINE Study (1692). Neurology. 94(15_supplement). 3 indexed citations

Montes, Jacqueline, Sally Dunaway Young, Elena Mazzone, et al.. (2018). Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy. (P2.322). Neurology. 90(15_supplement). 4 indexed citations

Kirschner, Janbernd, Eugenio Mercuri, Richard S. Finkel, et al.. (2017). Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): results of the phase 3 CHERISH study. Neuropediatrics. 48.

Dworetzky, Steven I., et al.. (2017). The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Molecules and Diseases. 63. 62–65. 34 indexed citations

Lally, Cathy, Cynthia C. Jones, Wildon Farwell, et al.. (2017). Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet Journal of Rare Diseases. 12(1). 175–175. 63 indexed citations

10.

He, Ping, Thomas Marbury, Wildon Farwell, et al.. (2014). Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function. The Journal of Clinical Pharmacology. 54(12). 1383–1390. 5 indexed citations

11.

Williams, James R., Douglas A. Kerr, & Wildon Farwell. (2013). Incidence of Serious Infections among Patients with ALS in a U.S. Health Insurance Claims Database (P07.086). Neurology. 80(7_supplement).

12.

Cudkowicz, Merit, Leonard H. van den Berg, Jeremy M. Shefner, et al.. (2013). Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology. 12(11). 1059–1067. 166 indexed citations

13.

Farwell, Wildon, Leonard DʼAvolio, Richard E. Scranton, Elizabeth Lawler, & J. Michael Gaziano. (2011). Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population. JNCI Journal of the National Cancer Institute. 103(11). 885–892. 83 indexed citations

14.

Farwell, Wildon, et al.. (2011). The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study. Cancer Causes & Control. 22(10). 1453–1459. 3 indexed citations

15.

DʼAvolio, Leonard, Wildon Farwell, & Louis D. Fiore. (2010). Comparative Effectiveness Research and Medical Informatics. The American Journal of Medicine. 123(12). e32–e37. 28 indexed citations

16.

DʼAvolio, Leonard, Tham Nguyen, Wildon Farwell, et al.. (2010). Evaluation of a generalizable approach to clinical information retrieval using the automated retrieval console (ARC). Journal of the American Medical Informatics Association. 17(4). 375–382. 59 indexed citations

17.

Hernandez, Rohini K., Wildon Farwell, Michael D. Cantor, & Elizabeth Lawler. (2009). Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System. Journal of the American Geriatrics Society. 57(11). 1997–2003. 79 indexed citations

18.

Taylor, Eric N., John P. Forman, & Wildon Farwell. (2007). Serum Anion Gap and Blood Pressure in the National Health and Nutrition Examination Survey. Hypertension. 50(2). 320–324. 63 indexed citations

19.

Farwell, Wildon, Howard D. Sesso, Julie E. Buring, & J. Michael Gaziano. (2005). Non–High-Density Lipoprotein Cholesterol Versus Low-Density Lipoprotein Cholesterol as a Risk Factor for a First Nonfatal Myocardial Infarction. The American Journal of Cardiology. 96(8). 1129–1134. 46 indexed citations

20.

Farwell, Wildon, Timothy E. Stump, Jane Wang, et al.. (2004). Weight gain and new onset diabetes associated with olanzapine and risperidone. Journal of General Internal Medicine. 19(12). 1200–1205. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact